Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.
- DOI
- 10.3390/pharmaceutics18101277
- Published
- 2026 Oct 9
- Container
- Pharmaceutics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/pharmaceutics18101277,
title = {Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.},
author = {Mateescu DM and Capraru ID and Enache B and Enache A and Precup CV and Buhaș CL and Muresan CO},
year = {2026},
journal = {Pharmaceutics},
doi = {10.3390/pharmaceutics18101277},
url = {https://doi.org/10.3390/pharmaceutics18101277}
}RIS
TY - JOUR TI - Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. AU - Mateescu DM AU - Capraru ID AU - Enache B AU - Enache A AU - Precup CV AU - Buhaș CL AU - Muresan CO PY - 2026 JO - Pharmaceutics DO - 10.3390/pharmaceutics18101277 UR - https://doi.org/10.3390/pharmaceutics18101277 ER -
APA
DM, M., ID, C., B, E., A, E., CV, P., CL, B., & CO, M. (2026). Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.. Pharmaceutics. https://doi.org/10.3390/pharmaceutics18101277
Source records
- pubmed · retrieved 2026-11-11T03:29:50.539Z